Total submissions: 3
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV001240996 | SCV001413985 | uncertain significance | Cohen syndrome | 2024-11-30 | criteria provided, single submitter | clinical testing | This sequence change replaces glutamine, which is neutral and polar, with arginine, which is basic and polar, at codon 3339 of the VPS13B protein (p.Gln3339Arg). This variant is present in population databases (rs558911841, gnomAD 0.01%). This variant has not been reported in the literature in individuals affected with VPS13B-related conditions. ClinVar contains an entry for this variant (Variation ID: 966343). An algorithm developed to predict the effect of missense changes on protein structure and function (PolyPhen-2) suggests that this variant is likely to be tolerated. Algorithms developed to predict the effect of sequence changes on RNA splicing suggest that this variant may disrupt the consensus splice site. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. |
Ambry Genetics | RCV004679036 | SCV005174719 | uncertain significance | Inborn genetic diseases | 2024-04-24 | criteria provided, single submitter | clinical testing | The c.10016A>G (p.Q3339R) alteration is located in exon 54 (coding exon 53) of the VPS13B gene. This alteration results from a A to G substitution at nucleotide position 10016, causing the glutamine (Q) at amino acid position 3339 to be replaced by an arginine (R). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. |
Natera, |
RCV001240996 | SCV002082726 | uncertain significance | Cohen syndrome | 2020-04-15 | no assertion criteria provided | clinical testing |